(Reuters) – Britain’s health regulator said on Tuesday it would introduce new measures for faster and easier approval and execution of clinical trials in the country.
The move comes months after an industry report showed that the number of annual clinical trials started in Britain dropped by 41% between 2017 and 2021, posing a “clear and serious threat” to its reputation as a clinical research destination.
“This overhaul of the clinical trials legislation will … help to streamline approvals by removing granular and duplicative regulatory requirements,” Marc Bailey, Chief Science and Innovation Officer at the Medicines and Healthcare products Regulatory Agency (MHRA) said.
An application review will need to be completed within 30 days, while a maximum of 10 days will be given for a decision to be granted, the regulator said.
The measures, which the MHRA said would be the biggest overhaul in two decades, will introduce a legal mandate to register the trial in a World Health Organisation public register, and will require publishing a summary of results within 12 months after the end of the trial.
(Reporting by Radhika Anilkumar in Bengaluru; Editing by Vinay Dwivedi)
